Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186328 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9180095 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US8999387 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9180096 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9017721 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9173854 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US8679544 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) |
Zorvolex is owned by Zyla.
Zorvolex contains Diclofenac.
Zorvolex has a total of 7 drug patents out of which 0 drug patents have expired.
Zorvolex was authorised for market use on 18 October, 2013.
Zorvolex is available in capsule;oral dosage forms.
Zorvolex can be used as treatment of pain.
The generics of Zorvolex are possible to be released after 23 April, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-692) | Aug 22, 2017 |
New Product(NP) | Oct 18, 2016 |
Drugs and Companies using DICLOFENAC ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treatment of pain
Dosage: CAPSULE;ORAL